Could a Senate drug pricing bill be 'a positive' for pharma? One analyst says so

COVID-19 pandemic, drug pricing talk has been mostly muted in Washington. But following the wins for Democrats in recent elections, Bernstein analyst Ronny Gal and his team see the issue gaining steam over the next few months.

Due to “deep public interest,” plus Congress’ growing familiarity with the subject and recent election results, Bernstein analysts figure drug pricing policy measures are “likely” in the Biden administration. But as the debate plays out, negotiations by lawmakers or administrative actions stand to affect just how much the pharma industry will feel the measures.